Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03671590
Title Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc.

chronic lymphocytic leukemia

B-cell lymphoma



Edralbrutinib + Ublituximab + Umbralisib

Age Groups: senior | adult
Covered Countries

No variant requirements are available.